Etanercept: An overview of its role in the treatment of psoriasis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 3, 2008, Pages 305-310

  Galindo, Malini Patel ^a   Bartlett, Brenda L ^a   Gewirtzman, Aron ^a   Mendoza, Natalia ^a   Tremaine, Anne Marie ^a   Tyring, Stephen K ^a  

^a CENTER FOR CLINICAL STUDIES   (United States)

Author keywords

Biologic therapy; Etanercept; Psoriasis; Tumor necrosis factor

Indexed keywords

ABT 874; ADALIMUMAB; ALEFACEPT; CNTO 1275; CYCLOPHOSPHAMIDE; DIGOXIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; LYMPHOTOXIN; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; USTIKINUMAB; WARFARIN;

ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; B CELL LYMPHOMA; BASAL CELL CARCINOMA; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FATIGUE; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; LEUKEMIA; LYMPHOMA; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHUMAN; OPTIC NEURITIS; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; POWDER; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RETREATMENT; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SOFT TISSUE CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SYRINGE; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMOMA; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; WEGENER GRANULOMATOSIS;

CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; IMMUNOGLOBULIN G; PRODUCT SURVEILLANCE, POSTMARKETING; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42949175148     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.3.305     Document Type: Review

References (36)

1. Tan JK, Aphale A, Malaviya R, et al. Mechanisms of action of etanercept in psoriasis. J Invest Dermatol Symp Proc 2007;12:38-45
2. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on Quality of Life. Arch Dermatol 2001;137:280-4
3. FDA approves first biologic therapy for psoriasis. FDA Talk Paper. Washington, DC: FDA/Center for Drug Evaluation and Rasearch, 2003. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/2003/ ANS01194.html [Last accessed 4 February 2008]
4. Papp KA. Potential future therapies for psoriasis. Semin Cutan Med Surg 2005;24:58-63
5. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monaclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92
6. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 2003;49:S105-11
7. Bonifati, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999;38:241-51
8. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-9
9. Malaviya R, Sun Y, Tan JK, et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 2007;55:590-7
10. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000;34:161-4
11. Zhou H. Clinical pharmacokinetics of etanercept a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 2005;45:490-7
12. Lebsack ME, Hanna RK, Lange MA, et al. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers. Pharmacotherapy 1997;17:1118
13. Nestorov I, Zitnik R, DeVries T, et al. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol 2006;62:435-45
14. Clark L Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008;58(3):443-6
15. Ostensen M, Eigenmann GO. Etanercept in breast milk J Rheumatol 2004;31:1017
16. Molta CT. Biologics in General Medicine. Berlin: Springer; 2007
17. Prescribing information for ENBREL®. Immunex Corporation, 2007. Available from: URL: www.enbrel.com/pdf/enbrel_pi.pdf [Last accessed 4 February 2008]
18. Thou H, Patat A, Parks V, et al. Absence of pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol 2004;44:543-50
19. Thou H, Parks V, Patat A, et al. Absence of a clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol 2004;44:1244-51
20. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32
21. Papp KA, Tyring S, Lahfa M, et al. A global Phase III randomized controlled trial of etanercept in psoriasis: safety efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12
22. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22
23. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of Etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26
24. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blinded placebo-controlled randomized Phase III trial. Lancet 2006;367:29-35
25. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007;56:598-603
26. Weinberd JM. An overview of infliximab. etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003;25:2487-505
27. Winterfield LS, Menter A, Gordon K, et al. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005;64:87-90
28. Gordon K, Leonardi CL, Gottlieb, et al. Safety of long-term etanercept treatment in patients with moderate to severe plaque psoriasis: an integrated, multistudy analysis
29. Strober B Observe-5. A 5-year, observational post-marketing safety surveillance registry of etanercept for the treatment of psoriasis. J Am Acae Dermatol 2007;AB181 (poster)
30. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development twenty-six cases reported to the Food and Drug Administration. Arthritis Rheuma 2002;46:3151-8
31. Mohan AK, Cote TR, Block, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9
32. Najia S, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359(9306):579
33. New drugs in development. Research pipeline. Portland, OR: National Psoriasis Foundation, 2007. Available from: URL: www.psoriasis.org/ research/pipeline/chart.php [Last accessed 4 February 2008]
34. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006,298:7-15
35. Downs AM. Adalimunab vs etanercept in psoriasis. Clin Exp Dermatol 2007;32:593
36. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007;57(6):957-62